bullish
Scivita Medical Technology (SMT HK) Pre-IPO: A Promising Game Changer with First-Mover Advantage
433 Views18 Dec 2021 22:40
SUMMARY
- Scivita Medical Technology (SMT HK) mainly focuses on single-use medical endoscopes, which comprises of three approved products and 11 pipeline products.
- Global single-use medical endoscope market is a limited competition market, with high growth potential. The risk of contamination will continue to be the key driver of single-use endoscopes.
- Scivita is at its early stage of commercialization in China and overseas market. Technical features of Scivita single-use endoscopes are comparable or superior to industry leader Ambu.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
x